Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, 6120 Executive Blvd (EPS), Suite 150E, MSC 7105, Bethesda, MD 20892, USA.
Br J Cancer. 2010 Sep 28;103(7):1097-102. doi: 10.1038/sj.bjc.6605844. Epub 2010 Aug 24.
Previous prospective studies have found an association between prolactin (PRL) levels and increased risk of breast cancer. Using data from a population-based breast cancer case-control study conducted in two cities in Poland (2000-2003), we examined the association of PRL levels with breast cancer risk factors among controls and with tumour characteristics among the cases.
We analysed PRL serum levels among 773 controls without breast cancer matched on age and residence to 776 invasive breast cancer cases with available pretreatment serum. Tumours were centrally reviewed and prepared as tissue microarrays for immunohistochemical analysis. Breast cancer risk factors, assessed by interview, were related to serum PRL levels among controls using analysis of variance. Mean serum PRL levels by tumour characteristics are reported. These associations also were evaluated using polytomous logistic regression.
Prolactin levels were associated with nulliparity in premenopausal (P=0.05) but not in postmenopausal women. Associations in postmenopausal women included an inverse association with increasing body mass index (P=0.0008) and direct association with use of recent/current hormone therapy (P=0.0006). In case-only analyses, higher PRL levels were more strongly associated with lobular compared with ductal carcinoma among postmenopausal women (P=0.02). Levels were not different by tumour size, grade, node involvement or oestrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 status.
Our analysis demonstrates that PRL levels are higher among premenopausal nulliparous as compared with parous women. Among postmenopausal women, levels were higher among hormone users and lower among obese women. These results may have value in understanding the mechanisms underlying several breast cancer risk factor associations.
先前的前瞻性研究发现催乳素(PRL)水平与乳腺癌风险增加之间存在关联。利用在波兰两个城市进行的基于人群的乳腺癌病例对照研究(2000-2003 年)的数据,我们检验了 PRL 水平与对照者中乳腺癌风险因素以及病例中肿瘤特征之间的相关性。
我们分析了 773 名年龄和居住地与 776 名可获得预处理血清的浸润性乳腺癌病例相匹配的无乳腺癌对照者的 PRL 血清水平。肿瘤经中心审查并制备成组织微阵列,进行免疫组织化学分析。通过面谈评估的乳腺癌风险因素与对照者的血清 PRL 水平相关,采用方差分析进行分析。按肿瘤特征报告平均血清 PRL 水平。还使用多项逻辑回归评估了这些关联。
PRL 水平与绝经前妇女的未婚状态相关(P=0.05),但与绝经后妇女无关。绝经后妇女的关联包括与体重指数增加呈负相关(P=0.0008)和与近期/当前激素治疗的直接相关(P=0.0006)。在仅病例分析中,绝经后妇女中,PRL 水平与小叶癌相比,与导管癌的相关性更强(P=0.02)。水平与肿瘤大小、分级、淋巴结受累或雌激素受体、孕激素受体或人表皮生长因子受体 2 状态无关。
我们的分析表明,PRL 水平在绝经前未育妇女中高于育后妇女。在绝经后妇女中,激素使用者的水平较高,肥胖妇女的水平较低。这些结果可能对理解几种乳腺癌风险因素关联的机制具有价值。